Following its announcement last week that it had sold its only commercial product to Septodont, Novalar is on the verge of shutting down completely, according to a story in the San Diego Tribune.
Novalar's 12 employees will be let go in the coming weeks as the company winds down operations, Donna Janson, president and CEO of Novalar, told the Tribune. Most of the 24 sales people hired by Novalar two years ago to launch the drug in the U.S. have already been laid off, she said.
Septodont, which has operations in North America, Europe, India, China, and Brazil, was already manufacturing OraVerse for Novalar.
